首页> 外文OA文献 >PCN46 Budget Impact Analysis of Bevacizumab Plus Chemotherapy Versus Bevacizumab and Anti-Egfr With Chemotherapy for First and Second Line Treatment of Metastatic Colorectal Cancer in Russian Federation

【2h】

PCN46 Budget Impact Analysis of Bevacizumab Plus Chemotherapy Versus Bevacizumab and Anti-Egfr With Chemotherapy for First and Second Line Treatment of Metastatic Colorectal Cancer in Russian Federation

机译：贝伐单抗联合化疗相对于贝伐单抗和抗Egfr联合化疗对转移性结直肠癌一线和二线治疗的PCN46预算影响分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Yagudina R.; Kulikov A.; Komarov I.;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis [J] . Shui L., Wu Y.-S., Lin H., Cellular Physiology and Biochemistry . 2018,第5期

机译：三联化疗（FOLFOXIRI）加贝伐单抗与双联化疗（FOLFOX / FOLFIRI）加贝伐单抗在转移性结直肠癌转化治疗中的Meta分析
2. Bevacizumab Continuation Versus Treatment Holidays After First-Line Chemotherapy With Bevacizumab in Patients With Metastatic Colorectal Cancer: A Health Economic Analysis of a Randomized Phase 3 Trial (SAKK 41/06) [J] . Matter-Walstra Klazien, Schwenkglenks Matthias, Betticher Daniel, Clinical colorectal cancer . 2016,第4期

机译：转移性结直肠癌患者接受贝伐单抗一线化疗后，贝伐单抗继续治疗与治疗假期：一项随机3期试验的健康经济分析（SAKK 41/06）
3. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial [J] . vonMinckwitzG., PuglisiF., CortesJ., The lancet oncology . 2014,第11期

机译：贝伐单抗联合化疗（TANIA）一线治疗后HER2阴性的局部复发或转移性乳腺癌患者，贝伐单抗联合化疗与单纯化疗作为二线治疗：一项开放性，随机，3期试验
4. Applying Quantitative Adiposity Feature Analysis Models to Predict Benefit of Bevacizumab-based Chemotherapy in Ovarian Cancer Patients [C] . Yunzhi Wang, Yuchen Qiu, Theresa Thai, Conference on medical imaging . 2016

机译：应用定量肥胖特征分析模型预测基于贝伐单抗的卵巢癌化疗获益
5. An economic analysis of the addition of bevacizumab to standard chemotherapy in patients with malignant pleural mesothelioma. [D] . Malacan, Jean. 2016

机译：恶性胸膜间皮瘤患者在标准化疗中加用贝伐单抗的经济分析。
6. Rationale and design of the TRUSTY study: a randomised multicentre open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy [O] . Takayuki Yoshino, Eiji Oki, Hiroaki Nozawa, 2018

机译：TRUSTY研究的原理和设计：三氟哌啶/替匹西酯加贝伐单抗与伊立替康氟嘧啶+贝伐单抗作为二线治疗的转移性结直肠癌患者在第一期或之后进展的随机多中心II / III期开放性研究基于奥沙利铂的化疗
7. PCN42 Budget Impact Analysis of Bevacizumab and Anti-Egfr with Chemotherapy for First and Second Line Treatment of Metastatic Colorectal Cancer in Russian Federation [O] . Yagudina R., Kulikov A., Komarov I. 2014

机译：贝伐单抗和抗Egfr联合化疗对俄罗斯联邦转移性结直肠癌的一线和二线治疗的PCN42预算影响分析

PCN46 Budget Impact Analysis of Bevacizumab Plus Chemotherapy Versus Bevacizumab and Anti-Egfr With Chemotherapy for First and Second Line Treatment of Metastatic Colorectal Cancer in Russian Federation

著录项

相似文献

相关主题

期刊订阅